- Home
- SCNX vs HIND Comparison
SCNX vs HIND Comparison
Compare SCNX & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SCNX | HIND |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Other Pharmaceuticals | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2M | 15.2M |
| IPO Year | 2019 | 2016 |
Fundamental Metrics
Financial Performance| Metric | SCNX | HIND |
|---|---|---|
| Price | $3.05 | $1.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.83 |
| AVG Volume (30 Days) | ★ 34.7K | 11.4K |
| Earning Date | 11-24-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 64.86 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,831,778.00 | $319,714.00 |
| Revenue This Year | $743.36 | N/A |
| Revenue Next Year | $325.03 | $82.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 30.72 | 24.43 |
| 52 Week Low | $2.64 | $1.55 |
| 52 Week High | $106.25 | $5.88 |
Technical Indicators
Market Signals| Indicator | SCNX | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 46.84 | 24.40 |
| Support Level | $2.64 | N/A |
| Resistance Level | $3.68 | $2.29 |
| Average True Range (ATR) | 0.24 | 0.11 |
| MACD | 0.24 | -0.02 |
| Stochastic Oscillator | 43.27 | 0.00 |
Price Performance
Historical ComparisonAbout SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
About HIND Vyome Holdings Inc.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.